Investment thesis

New management at Herbalife is attempting to transform Herbalife from a legacy MLM nutrition company into a technology-driven personalized wellness platform. Early results show stabilizing sales growth, improving EBITDA margins, and successful debt reduction. The critical question is whether the personalized nutrition pivot (via Bioniq, Pro2col) can successfully differentiate Herbalife and rerate its severely depressed valuation (P/E ~7x vs. historical ~12x).

The market is responding to these changes. The stock has more than tripled from its low last year.

Herbalife Ltd. is a global health and wellness company operating in over 90 countries, primarily using a multi-level marketing (MLM) model to distribute weight management, nutrition, sports/fitness, and personal care products. The company has undergone significant transformation after regulatory and pandemic headwinds, refreshing its brand platform and expanding into sports nutrition with a sharper digital go-to-market approach.

Herbalife has a PE Ratio of 7.58 and FCF Yield of 14.67%. ROIC of 17% is strong. Growth is flat to tepid though the company has begun to show decent growth in operating income in recent quarters. Business appears to have stabilized post introduction of GLP-1 drugs like Ozempic and Wegovy. https://userupload.gurufocus.com/2044227690915078144.png

Balance Sheet

The company carries significant debt relative to negative equity, but strong operating cash flow ($333M) and an undrawn credit facility provide liquidity cushion. The leverage ratio of 2.91x is manageable given consistent cash generation. However, negative shareholders' equity (-$606M) is concerning and reflects historical challenges including share buybacks and accumulation deficits. Management has successfully bought the debt load and leverage down over the last 3 years.

Prominent Value Investor Seth Klarman (The Baupost Group) has bought ~9% of the outstanding shares and has continued to buy as the stock recovers.